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Background: Bisphosphonates are widely used for the treatment of osteoporosis and 
other bone degrading disorders; however, bisphosphonate therapy is an important risk 
factor for osteonecrosis of the jaws. Methods: We report a rare case of 
bisphosphonate-related osteonecrosis of the palatal torus. Results: The patient was a 
72-year-old female with osteoporosis who had received 35 mg alendronate sodium 
hydrate once every week for 6 years. She had a 2-month history of oral pain because of 
intractable mucositis and ulceration of the palatal torus, with no history of malignant 
disease, radiation therapy, chemotherapy, steroid use, or recent dentoalveolar surgery. A 
CT scan showed a bony prominence at the midportion of the hard palate with erosion of 
its cortex. Her condition was diagnosed as stage 2 bisphosphonate-related osteonecrosis 
of the jaw (BRONJ) caused by trauma and she was advised to discontinue alendronate. 
She was prescribed oral antibiotics for 5 days and an oral antibacterial rinse. The 
mucositis with ulceration healed in approximately 10 weeks, but left a small scar. 
Conclusions: Although osteonecrosis of the palatal torus associated with 
bisphosphonate use is a rare condition, otolaryngologists should consider this condition 










Bisphosphonates are widely used for the treatment of osteoporosis and other bone 
degrading disorders, although bisphosphonate-related osteonecrosis of the jaw (BRONJ) 
have been reported since 2003 [1, 2]. However, many otolaryngologists appear to have 
little understanding of this significant complication. Here we report a rare case of 




A 72-year-old female experienced oral pain after eating hot food one day. She visited an 
ENT clinic where she was diagnosed with mucositis with ulceration of the hard palate. 
She was instructed to apply a steroidal ointment for treatment of the mucositis, but there 
was no sign of improvement after 2 months. Thereafter, she was encouraged to undergo 
a biopsy and visited our hospital for further examination after recommendation from the 
ENT clinic. She presented with a chief complaint of sustained pain in the palate. Her 
medical history revealed osteoporosis, which had been treated with 35 mg of 
alendronate sodium hydrate once per week for 6 years. She had no history of malignant 
disease, radiation therapy, chemotherapy, steroid use, or recent dentoalveolar surgery. 
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Physical examination revealed an ulcer with a diameter of 1 cm, with exposure of the 
bone of the palatal torus (fig. 1). No abnormal blood vessels were observed in the 
mucosa surrounding the ulcer by narrow-band imaging (NBI) [3, 4]. She had 28 teeth 
except the 4 third molars and had neither tooth caries nor periodontal disease. The 
results of hematological examination were normal. A CT scan showed a bony 
prominence at the midportion of the hard palate with erosion of its cortex (fig. 2). 
Although we did not perform a biopsy of the palate, we diagnosed her condition as 
stage 2 bisphosphonate-related osteonecrosis of the palatal torus caused by trauma and 
advised her to discontinue alendronate. We prescribed an oral antibiotic (cefdinir) for 5 
days and an oral antibacterial rinse. Bacterial examination was not performed. The ulcer 
began to shrink 7 weeks after discontinuation of alendronate. After 3 additional weeks, 
the ulcer was healed, but left a small scar, and the oral pain ceased. After recovery from 
osteonecrosis, she declined resection of the palatal torus. Her orthopedist determined 
that she did not need to restart bisphosphonate therapy. There has been no recurrence of 
symptoms or ulceration for 6 months. 
 
Discussion 
BRONJ is a potential serious side effect of bisphosphonate therapy. The incidence of 
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BRONJ in patients receiving weekly alendronate therapy is estimated at 0.01%–0.04% 
[5]. The risk factors for BRONJ include drug-related factors (bisphosphonate potency 
and duration of therapy), local factors (dentoalveolar surgery, local anatomy of the jaw 
including tori and ridge, and concomitant oral disease), demographic and systemic 
factors (e.g., age, renal dialysis, low hemoglobin levels, obesity, and diabetes), genetic 
factors, and preventative factors (e.g., manipulation of intravenous bisphosphonate 
dose) [6]. The 2 most important risk factors for BRONJ are intravenous bisphosphonate 
administration and dentoalveolar procedures [6]. The mucosa overlying bony 
prominences such as tori are possibly injured while eating. Marx et al. found that 9.2% 
of patients with BRONJ had their exposed bone over the mandibular tori [7], but 
BRONJ cases involving the palatal tori are comparatively rare [8-10].  
According to a position paper on BRONJ by the American Association of Oral and 
Maxillofacial Surgeons, patients may be considered to have BRONJ if all the following 
3 characteristics are present: (1) current or previous treatment with a bisphosphonate; 
(2) exposed bone in the maxillofacial region that has persisted for more than 8 weeks; 
and (3) no history of radiation therapy to the jaws [6]. The patient in our case met all 3 
conditions and no abnormal blood vessels were observed in the mucosa surrounding the 
ulcer on NBI; thus, we made a diagnosis of BRONJ without a biopsy. According to 
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Ruggiero et al., biopsies are not recommended for BRONJ in cancer patients 
undergoing bisphosphonate treatment unless metastasis to the jaw is suspected, because 
the benefit of a confirmed biopsy does not outweigh the risk of inducing further bone 
damage that could exacerbate the condition [11]. We must judge carefully whether we 
should perform a biopsy when a patient has the aforementioned 3 characteristics so as to 
not deteriorate the condition. Then NBI will be helpful for detecting superficial oral 
squamous cell carcinomas because it is an optical technique that enhances the diagnostic 
capability of endoscopy by illuminating the intraepithelial papillary capillary loop by 
means of narrow and wide filters in a red–green–blue sequential illumination system [3, 
4]. If a malignancy is suspected, a biopsy should be performed to confirm the diagnosis 
at any stage of the disease. 
BRONJ is classified into 4 stages, stage 0–3 [6]. In our case, we categorized BRONJ 
as stage 2 because exposed and necrotic bone was observed over a limited area, 
accompanied by pain and clinical evidence of infection. The position paper states that 
patients with stage 2 BRONJ can benefit from the use of oral antimicrobial rinses and 
antibiotic therapy, and if systemic conditions permit, oral bisphosphonate therapy 
should be modified or ceased after consultation with the treating physician and the 
patient [6]. Our patient successfully recovered from BRONJ with only conservative 
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therapy using oral rinses and antibiotics, in combination with discontinuation of 
alendronate. Though penicillin is recommended in the position paper [6], we used 
cefdinir for antibiotic therapy because it has insurance indication for periodontitis in 
Japan. 
In previous reports of osteonecrosis of the palatal tori, surgical removal of the torus [8] 
and necrotic bone [9] was performed after bisphosphonate treatment was discontinued. 
Lo et al. reported 3 patients with stage 1–2 BRONJ involving the palatal tori and 
spontaneous exfoliation occurred in 2 patients [10]. If the exposed and necrotic bone 
extends over wide areas (stage 3), debridement will be useful; regardless of the disease 
stage, mobile segments of bony sequestrum should be removed without exposing 
uninvolved bone, as recommended by the position paper [6]. Furthermore, after 
recovery from BRONJ, removal of the palatal tori should be considered if the patient 
restarts bisphosphonate therapy, particularly by the intravenous route. To prevent 
BRONJ, Marx et al. recommended removal of the palatal tori 1 month before initiation 
of bisphosphonate therapy [7]. 
Most BRONJ cases have been reported in the dental literature; thus, this condition 
remains unfamiliar to many otolaryngologists. However, otolaryngologists may 
encounter BRONJ cases and should, therefore, become more familiar with this 
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condition. BRONJ involving the palatal tori is atypical and may be difficult to be 
correctly diagnose if the examining physician fails to associate it with bisphosphonate 
exposure. Correct diagnosis of BRONJ can avoid unnecessary biopsy and possible 
exacerbation of the condition by facilitating appropriate treatment. 
 
Conclusions 
Although osteonecrosis of the palatal torus associated with bisphosphonate therapy is a 
rare condition, otolaryngologists should consider this condition in the differential 
diagnosis of intractable ulceration of the hard palate. 
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Fig. 1. Photographs of the palatal torus. Ulcer formation with exposure of the cortical 




Fig. 2. Axial CT scan. The cortex of the palatal torus was eroded. 
 


